Astrazeneca (AZN) EBIT Margin (2009 - 2026)

Astrazeneca (AZN) has reported EBIT Margin for 18 consecutive years, with 5514.29% the latest figure, recorded in Q1 2026.

• In Q1 2026, EBIT Margin rose 54942.0% year-over-year to 5514.29%; the TTM figure through Mar 2026 stood at 14034.31% (up 1292486.0% YoY), while the FY2025 annual figure was 23.4%, down 106035.0% from the prior year.
• EBIT Margin came in at 5514.29% for Q1 2026 at Astrazeneca, down from 49633.33% in the prior quarter.
• The five-year high for EBIT Margin was 68650.0% in Q2 2024, with the low at 249.82% in Q4 2024.
• Average EBIT Margin over 5 years is 14635.22%, with a median of 4964.86% recorded in 2025.
• Across the five-year window, EBIT Margin surged 6737746 bps in 2024 and plunged 2480000 bps in 2025, its largest moves.
• Year by year, EBIT Margin stood at 692.41% in 2022, then tumbled by 36 bps to 445.49% in 2023, then slumped by 44 bps to 249.82% in 2024, then soared by 19768 bps to 49633.33% in 2025, then plunged by 89 bps to 5514.29% in 2026.
• According to Business Quant data, EBIT Margin over the past three periods registered 5514.29%, 49633.33%, and 32572.73% for Q1 2026, Q4 2025, and Q3 2025 respectively.